期刊文献+

地西他滨联合CAG方案治疗复发难治性急性髓系白血病的护理分析 被引量:6

Nursing Analysis of Decitabine Combined With CAG Regimen in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
下载PDF
导出
摘要 目的分析地西他滨联合CAG方案治疗复发难治性急性髓系白血病的护理效果。方法选取我院收治的15例复发难治性急性髓系白血病患者,均给予地西他滨联合CAG方案治疗,并给予对症护理,观察护理效果。结果在经过治疗后,完全缓解患者9例,部分缓解患者5例,无效患者1例。结论应用地西他滨联合CAG方案进行治疗可以取得良好的治疗效果,同时,结合有效、科学、及时的对症护理能够有效缓解的不良反应,引导患者积极配合治疗,帮助患者早日恢复健康。 Objective To investigate the effect of decitabine combined with CAG regimen in the treatment of relapsed and refractory acute myeloid leukemia and nursing effect. Methods Selected 15 cases of recurrence in our hospital of refractory acute myeloid leukemia patients who were treated with decitabine combined with CAG regimen,and gave symptomatic nursing,observed the nursing effect . Results After treatment,to complete remission in 9 patients,5 cases of patients with partial remission,1 cases were invalid. Conclusion Application of CAG combination solution treatment can achieve good treatment effect, at the same time, combined with effective, scientific, timely symptomatic nursing can effectively al eviate the adverse reaction, guide actively cooperate with treatment, help patients recover earlier.
作者 刘迎庆
出处 《中国卫生标准管理》 2015年第13期229-230,共2页 China Health Standard Management
关键词 地西他滨 CAG方案 复发难治性急性髓系白血病 护理效果 Decitabine CAG scheme Refractory relapsed acute myeloid leukemia Nursing effect
  • 相关文献

参考文献4

二级参考文献25

  • 1刘传芳,侯明,陈学良,张青春,栾海英,王蓝萍,毕作木,张茂宏.CAG方案治疗复发难治急性髓系白血病[J].中华血液学杂志,2004,25(6):384-384. 被引量:4
  • 2张青,韩明哲,秘营昌,肖志坚,邱录贵,冯四洲,杨仁池,李睿,卞寿庚,王建祥.FLAG方案治疗难治、复发性急性髓系白血病的临床研究[J].中华血液学杂志,2005,26(11):682-684. 被引量:18
  • 3钟济华,陈芳源,王海嵘,黄洪晖,钟华,韩洁英,宣正华,欧阳仁荣.CAG方案对急性髓系白血病细胞作用机制的研究[J].中华血液学杂志,2006,27(7):492-494. 被引量:25
  • 4Kantarjian H, Issa JP, Rosenfeld CS. Decitabine improves pa- tient outcomes in myelodysplastic syndromes; results of a phase HI randomized study[J].Cancer, 2006, 106: 1794- 1803.
  • 5Kantarjian H,Oki Y,Garcia-Manero G,et al. Results of a ran- domized study of 3 schedules of low-dose decitabine in higher- risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109( 1 ) :52-57.
  • 6Ravandi F, Kantarjian H, Giles F, et al. New agents in acute myeloid leukemia and other myeloid disorders [ J ]. Cancer, 2004.100:441-454.
  • 7Cashen A, Schiller G, Larsen JS, et al. Phase II study of low- dose decitabine for the front line treatment of older patients with acute myeloid leukemia ( AML ) [ J ]. Blood, 2006,108 : 561.
  • 8Scandura JM, Roboz GJ. Phase I study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML [ J ]. Blood, 2011,118 : 1472-1480.
  • 9Harris NL, Jaffe ES, Diebold J, et al.World health organization classi fication of neoplastic diseases of the hematopoietic and lymphoid tis sue:report of the clinical advisory committee meeting-Airlie house Virginia, November 1997[J]. J Clin Oncology, 1999,17( 12 ):3835- 3849.
  • 10董玉玮,侯进慧,朱必才,等.表观遗传学的相关概念和研究进展[J].生命的化学,2005,22(1):1-3.

共引文献70

同被引文献39

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部